<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

New Oral Medication Approved for Metastatic Colorectal Cancer

According to the National Cancer Institute, Colorectal cancer (CRC) is the third most common non-skin cancer in men and women in the U.S. and the second leading cause of cancer-related death. In the last 10 years the number of disease-related deaths have declined, partly due to more frequent screenings. On September 22nd the U.S. FDA approved Lonsurf for patients with an advanced form of colorectal cancer who are no longer responding to other therapies.

Fluoropyrimidines are a category of drugs widely used in the treatment of a variety of cancer types including colorectal and breast cancer or cancers of the aerodigestive tract. They work by interfering with DNA synthesis leading to tumor cell death. 5-Fluorouracil (5-FU), one of the most popular drugs in this category, was first synthetized in 1957 but soon enough the need for more convenient and efficacious fluoropyrimidine therapy was evident since 5-FU needed to be administered over long periods of time via intravenous infusion and patients eventually relapsed, becoming resistant to treatment.

Trifluridine is the fluoropyrimidine component of Lonsurf. Phase I and Phase II clinical trials of intravenous trifluridine alone initially proved disappointing since the drug was rapidly degraded once in the blood stream and tumors rapidly recurred upon termination of therapy. Thanks to significant progress in the understanding of the pharmacokinetic of trifluridine, it became clear that when taken orally, the drug was more stable especially if administered in combination with a thymidine phosphorylase inhibitor (TPI), a compound that blocks trifluridine degradation.

The formulation of Lonsurf is based on the knowledge acquired over the years for this class of compounds. In Lonsurf trifluridine is combined with tipiracil – a TPI – and this combination is indicated for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and an anti-EGFR therapy - in the case of patients with wild-type RAS.

Lonsurf efficacy and safety were evaluated in the RECOURSE international, randomized, double-blind trial involving 800 patients with previously treated metastatic colorectal cancer. The primary endpoint of the study was overall survival and the secondary endpoint was progression-free survival. Patients treated with Lonsurf lived longer compared to those treated with placebo and stayed disease-free for a longer period of time, providing patients and their oncologists with a novel oral therapy.

Lonsurf is manufactured by Taiho Oncology Inc., and was already approved in Japan early this year, based on findings from Phase II studies.

Crown Bioscience is happy to see that progress is being made in the treatment of metastatic CRC. At Crown we recognize that the high attrition rate in oncology drug development still represents a significant challenge for pharma and biotechs, with around 60% of failures coming in Phase II testing onwards. Most oncology drug failures are linked to efficacy issues (not toxicity) and can be attributed to poor preclinical strategies and a lack of an effective associated clinical plan. Translational platforms are needed which can identify the correct set of patient responders for a drug, in order to focus clinical study on using the right drug, for the correct indication, within the right cancer subpopulation.

At Crown Bioscience we are pioneers in the use of patient-derived xenograft (PDX) models to ensure the highest likelihood of success when moving new drugs in to the clinic. We have generated HuPrime® the world’s largest commercial collection of over 1,600 patient-derived xenograft models, which allows research into over 20 different cancer indications, and a variety of subtypes. Using these models in our Translational Platforms HuTrial, HuSignature, and HuMark allows clients to utilize precision profiling to identify molecular biomarkers and genetic signatures of response before entering the clinic. Finding your responder population before entering late-phase clinical trials is the best way to stratify potential clinical trial participants, increasing the likelihood of response, and reducing attrition rate.

Contact us today at busdev@crownbio.com for any further questions or information on our CRC PDX models and services.


Related Posts